According to the Authors, the barrier defect plays an important role not only in dermatitis but also in other atopic conditions. While not ignoring the role of defect in immune regulation, in the latest systematic review the role of emollients is re-evaluated especially in the prevention of exacerbations of atopic dermatitis. Not all the emollients are the same and the most interesting are those that, thanks to the use of natural anti-inflammatory substances and prebiotics, seem to be able to decrease the itching and make the life of Staphylococcus aureus more difficult. In particular, the efficacy and tolerability of RILASTIL XEROLACT ATOPIC balm 1 and bath oil 2 were studied leading the Authors to conclude that they can represent a useful tool in the armament of the physician that must cure atopic dermatitis.

Observational clinical study of a new emollient in 26 patients with atopic dermatitis / C. Rigoni, A.M. Cantù, C. Gelmetti. - In: PD. EUROPEAN JOURNAL OF PEDIATRIC DERMATOLOGY. - ISSN 1122-7672. - 28:4(2018), pp. 218-225. [10.26326/2281-9649.28.4.1917]

Observational clinical study of a new emollient in 26 patients with atopic dermatitis

C. Gelmetti
Ultimo
2018

Abstract

According to the Authors, the barrier defect plays an important role not only in dermatitis but also in other atopic conditions. While not ignoring the role of defect in immune regulation, in the latest systematic review the role of emollients is re-evaluated especially in the prevention of exacerbations of atopic dermatitis. Not all the emollients are the same and the most interesting are those that, thanks to the use of natural anti-inflammatory substances and prebiotics, seem to be able to decrease the itching and make the life of Staphylococcus aureus more difficult. In particular, the efficacy and tolerability of RILASTIL XEROLACT ATOPIC balm 1 and bath oil 2 were studied leading the Authors to conclude that they can represent a useful tool in the armament of the physician that must cure atopic dermatitis.
Atopic dermatitis; Emollients; Pediatrics, Perinatology and Child Health; 2708
Settore MED/35 - Malattie Cutanee e Veneree
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
gelmetti-studio-nuovo-emolliente.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 838.48 kB
Formato Adobe PDF
838.48 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/631753
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact